Skip to Content

Sanofi SA - Stock Quote SAN

Rating as of

Morningstar's Sanofi SA Stock Analysis

Valuation
Currency in EUR
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Buoyed by Dupixent, Undervalued Sanofi Posts Solid 1Q, a Robust Trend Expected for Many Years Ahead

Damien Conover, CFA Sector Director

Analyst Note

| Damien Conover, CFA |

Sanofi reported solid first-quarter results, slightly above our expectations, but we don’t expect any major changes to our fair value estimate based on the minor outperformance. We continue to view the stock as undervalued with the market not fully appreciating the firm’s growth potential from currently marketed drugs and new pipeline products that also support the firm’s wide moat.

Read Full Analysis

Sanofi SA's Company Profile

Business Description

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

Contact
54, Rue La Boetie
Paris, 75008, France
T +33 153774000
Sector Healthcare
Industry Drug Manufacturers - General
Most Recent Earnings Dec 31, 2021
Fiscal Year End Dec 31, 2022
Stock Type
Employees 95,442

Sanofi SA's Related News